::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::

CODEN : IAJPBB
issn 2349-7750

News Updates Latest Volumes: COSMOS IMPACT FACTOR (2018)- 4.153, GLOBAL IMPACT FACTOR(2014) - 0.384, (2015) - 0.437, Indo American Journal of Pharmaceutical Sciences,

ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

SEVERITY OF COVID-19 PATIENTS DEALING WITH ACE INHIBITORS, ARBS, HYPERTENSION, PNEUMONIA AND DIABETES-A REVIEW ARTICLE

AUTHORS:

Dr Bilal Hussain, Dr Aqsa Saeed, Dr Muhaamad Arsalan Ali Sajid, Dr Awais Ahmed Uttra, Dr Awais Mushtaq

ABSTRACT:

Concerns exists that angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) increase susceptibility to coronavirus SARS CoV-2 (the viral agent that causes the disease COVID-19) and the likelihood of severe COVID-19 illness. Millions of people around the world are on treatment with ACE-inhibitors and ARBs for hypertension, heart failure, coronary artery disease, or kidney disease. Speculation about worse outcomes among patients on these medications during the COVID-19 pandemic has caused widespread anxiety among patients and their care providers. This article is based on different effects of COVID-19 on those patients with other severe diseases like hypertension, pneumonia, diabetes etc. It also explains that whether angiotensin-converting enzyme inhibitors have any bad impact on these patients if they continue to use these drugs. Keywords: Covid-19, SARS-COV-2, ACE inhibitors, ARBs Hypertension, Diabetes and Pneumonia.